Memed seeks partners for bacterial vs viral testing and more
The group’s ambitions are startling, but it will need cash and collaborators to realise them.
The heat is on for Oxford Nanopore
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
Breakthrough device reimbursement rule on the rocks
Despite industry outcry, new data question how relevant the rule would have been anyway.
